Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint Maplight Therapeutics (
NASDAQ:MPLT ) reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen producing a statistically significant improvement in Positive and Negative Syndrome Scale, or PANSS, total scores versus placebo at five w
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? This clinical-stage biotech focused on CNS disorders reported a notable insider sale amid ongoing development of its neurology pipeline.
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April This clinical-stage biotech focused on CNS disorders reported a notable insider sale in its latest SEC filing.
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data This clinical-stage biotech focused on CNS disorders reported a notable insider sale, as disclosed in its latest SEC filing.
